Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the first data presentation supporting the use of EXPAREL ® (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane (TAP) for postsurgical pain management. TAP infiltration is being increasingly utilized for postsurgical analgesia in abdominal procedures as clinicians aim to maintain pain control while reducing reliance on opioid analgesics. Andrew Sternlicht, M.D., Assistant Clinical Professor of Anesthesiology at the Tufts University School of Medicine, is lead author on a poster presentation of the data, which will be presented at the 11 th Annual American Society of Regional Anesthesia and Pain Medicine (ASRA) Meeting, taking place November 15-18, 2012 in Miami. Twenty-four patients undergoing robotic prostatectomy were enrolled in this open-label, prospective study to evaluate the efficacy and safety of EXPAREL via TAP infiltration. Key findings include:
- Patients required a mean of less than one oxycodone/acetaminophen tablet per day from their discharge until their day 10 visit.
- 100 percent of the available subjects reported being either satisfied or extremely satisfied with their postsurgical pain control at hospital discharge, at 72 hours and on day 10.
- When retrospectively compared to a 2011 study of patients who received a TAP infiltration of bupivacaine HCl, patients administered EXPAREL in the same fashion had similar or better pain scores with a reduced requirement for opioids.
Findings indicate that inadequately controlled postsurgical pain is ubiquitous:
- More than 85 percent of the patients surveyed reported experiencing postsurgical pain.
- Seventy-five percent of patients reporting pain characterized it as moderate, severe or extreme.
- Seventy-nine percent of patients reported experiencing side effects from pain medications, with the majority of those side effects appearing to be opioid-related.
Please see the full Prescribing Information for more details available at www.EXPAREL.com.